Cargando…
Best regimens for treating chemo‐naïve incurable squamous non‐small cell lung cancer with a programmed death‐ligand 1 tumor proportion score of 1%–49%: A network meta‐analysis
BACKGROUND: Non‐small cell lung cancer (NSCLC) is the leading cause of cancer‐related mortality worldwide. It is advisable to select the appropriate treatment based on characteristics of the cancer such as pathology, mutations, and programmed death‐ligand 1 (PD‐L1) levels. In this study, by remarkin...
Autores principales: | Fukuda, Nobuhiko, Horita, Nobuyuki, Namkoong, Ho, Kaneko, Ayami, Somekawa, Kohei, Tagami, Yoichi, Watanabe, Keisuke, Hara, Yu, Kobayashi, Nobuaki, Kaneko, Takeshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720615/ https://www.ncbi.nlm.nih.gov/pubmed/34791815 http://dx.doi.org/10.1111/1759-7714.14229 |
Ejemplares similares
-
The best regimens for chemo-naïve incurable non-squamous non-small cell lung cancer with a programmed death-ligand 1, tumor proportion score 1–49%: a network meta-analysis
por: Fukuda, Nobuhiko, et al.
Publicado: (2021) -
The best platinum regimens for chemo-naive incurable non-small cell lung cancer: network meta-analysis
por: Horita, Nobuyuki, et al.
Publicado: (2017) -
Adverse events induced by nivolumab and ipilimumab combination regimens
por: Somekawa, Kohei, et al.
Publicado: (2022) -
Adverse events induced by durvalumab and tremelimumab combination regimens: a systematic review and meta-analysis
por: Matsumoto, Hiromi, et al.
Publicado: (2023) -
Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non‐small‐cell lung cancer: A multicenter retrospective trial
por: Matsumoto, Hiromi, et al.
Publicado: (2021)